InflaRx N.V.
General ticker "IFRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $93.2M (TTM average)
InflaRx N.V. follows the US Stock Market performance with the rate: 4.3%.
Estimated limits based on current volatility of 3.2%: low 0.89$, high 0.94$
Factors to consider:
- Earnings expected soon, date: 2026-03-19 bmo
- Total employees count: 21 as of 2017
- Current price 36.3% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.53$, 4.02$]
- 2025-12-31 to 2026-12-31 estimated range: [1.44$, 3.74$]
Financial Metrics affecting the IFRX estimates:
- Positive: with PPE of -2.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -35.66 <= 0.01
- Positive: Investing cash flow per share per price, % of 38.45 > -0.63
- Positive: Inventory ratio change, % of -1.80 <= -0.75
- Positive: Shareholder equity ratio, % of 80.79 > 64.29
- Negative: negative Net income
Short-term IFRX quotes
Long-term IFRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | €0.06MM | €0.17MM |
| Operating Expenses | €44.97MM | €53.17MM |
| Operating Income | €-44.91MM | €-53.01MM |
| Non-Operating Income | €2.24MM | €6.95MM |
| Interest Expense | €0.04MM | €0.02MM |
| R&D Expense | €41.02MM | €35.36MM |
| Income(Loss) | €-42.67MM | €-46.06MM |
| Taxes | €0.00MM | €0.01MM |
| Profit(Loss)* | €-42.67MM | €-46.06MM |
| Stockholders Equity | €102.58MM | €61.42MM |
| Inventory | €11.37MM | €6.90MM |
| Assets | €120.21MM | €76.02MM |
| Operating Cash Flow | €-37.81MM | €-48.56MM |
| Capital expenditure | €0.08MM | €0.05MM |
| Investing Cash Flow | €-17.70MM | €52.36MM |
| Financing Cash Flow | €52.99MM | €0.39MM |
| Earnings Per Share** | €-0.78 | €-0.78 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.